Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.TCRT · Entity 8339 | Director | October 06, 2026 | October 08, 2026 |
| Inhibitor Therapeutics, Inc.INTI · Entity 7783 | Director | May 04, 2026 | June 24, 2026 |
| MIRA PHARMACEUTICALS, INC.MIRA · Entity 7362 | Director | March 25, 2024 | March 27, 2024 |
| Telomir Pharmaceuticals, Inc.TELO · Entity 6962 | Director | August 27, 2024 | August 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,749 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 20,990 · Balance 44,749 F1: Represents shares of common stock issued in lieu of board fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued in lieu of board fees.
Inhibitor Therapeutics, Inc.
Report date May 04, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 180,411 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 50,000 · Balance 180,411 F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan.
MIRA PHARMACEUTICALS, INC.
Report date March 25, 2024 · Filed March 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.16 · Expires 2034-03-25 | Direct | 25,000 |
Reported balance
After 2024-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-25 · Grant · Acquired 50,000 · Balance 25,000 F1: The options were granted under the Issuer's 2022 Omnibus Incentive Plan whereby 50% of such options, or 25,000 options, vested immediately on the grant date of March 25, 2024, and the remaining 50% vest on the first anniversary of the grant date, March 25, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted under the Issuer's 2022 Omnibus Incentive Plan whereby 50% of such options, or 25,000 options, vested immediately on the grant date of March 25, 2024, and the remaining 50% vest on the first anniversary of the grant date, March 25, 2025.
Telomir Pharmaceuticals, Inc.
Report date August 27, 2024 · Filed August 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02 · Expires 2034-08-27 | Direct | 25,000 |
Reported balance
After 2024-08-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-27 · Grant · Acquired 25,000 · Balance 25,000 F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. F2: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024.
F2: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 20:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 20,990 | $0.74 | $15,624.96 |
DisclosureSEC source: 0001193125-26-417974 · ownership.xml · nonDerivative · entry 1 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,749 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:15 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 8,138 | $1.92 | $15,624.96 |
DisclosureSEC source: 0001193125-26-318114 · ownership.xml · nonDerivative · entry 1 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,759 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| May 04, 2026 Filed Jun 24, 2026 16:34 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-029898 · ownership.xml · nonDerivative · entry 1 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,411 F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:15 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 6,032 | $2.59 | $15,622.88 |
DisclosureSEC source: 0001193125-26-201474 · ownership.xml · nonDerivative · entry 1 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,621 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 21:15 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 5,406 | $2.89 | $15,623.34 |
DisclosureSEC source: 0001193125-26-014117 · ownership.xml · nonDerivative · entry 1 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,589 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| November 21, 2025 Filed Nov 27, 2025 02:26 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 4,183 | $3.16 | $13,218.28 |
DisclosureSEC source: 0001193125-25-301025 · ownership.xml · nonDerivative · entry 1 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,183 F1 · price: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:35 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 3,200 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000950170-25-096674 · ownership.xml · derivative · entry 2 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires 2035-07-14 F2 · derivative.exercise_date: One-twelfth of the Option vests each month on the monthly anniversary of July 15, 2025, with any amount that remains unvested on the date immediately preceding the Company's 2026 annual general meeting of stockholders vesting thereon. Vesting shall accelerate in full upon Optionholder's death or Disability or a Change of Control. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 21:35 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0000950170-25-096674 · ownership.xml · derivative · entry 1 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-07-14 F1 · derivative.exercise_date: One-thirty sixth of the shares underlying the option vest in equal monthly installments measured from December 29, 2023, with the first vesting occurring on January 29, 2024, subject to the Reporting Person's continued service through each such date. Read SEC document |
| April 01, 2025 Filed Apr 7, 2025 21:21 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-003023 · ownership.xml · nonDerivative · entry 1 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,411 F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:05 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | GrantIncentive Stock Options (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001493152-24-034373 · ownership.xml · derivative · entry 1 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-08-27 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. F2 · balance_after: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). Fifty percent of the stock options vested immediately upon issuance and the remaining fifty percent of the stock options are to vest on February 26, 2025. Read SEC document |
| April 01, 2024 Filed May 16, 2024 17:34 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-020170 · ownership.xml · nonDerivative · entry 1 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,411 F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 21:53 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantNonqualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001493152-24-011571 · ownership.xml · derivative · entry 1 Jerman Michael Allen · CIK 0001979732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 50,000 shares Expires 2034-03-25 F1 · derivative.exercise_date: The options were granted under the Issuer's 2022 Omnibus Incentive Plan whereby 50% of such options, or 25,000 options, vested immediately on the grant date of March 25, 2024, and the remaining 50% vest on the first anniversary of the grant date, March 25, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.